// App-Quantinova.ai

1333 : Treatment of acute attacks of hereditary angioedema due to C1 inhibitor deficiency with icatibant in paediatric versus adult patients: Findings from the icatibant outcome survey

Researchers

Presenter

  • Longhurst H. J

Principal Investigators

  • Bouillet L

  • Aberer W

  • Caballero T

  • Grumach AS

  • Botha J

  • Andresen I

  • Maurer M

Medical Centers

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University, Grenoble, France

  • Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria

  • Department of Allergy, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain

  • Clinical Immunology, Medical School, University Center Health ABC, Santo Andre, Brazil

  • Shire, a Takeda Company, Zug, Switzerland

  • Dermatological Allergology, Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité Universitätsmedizin, Berlin, Germany

Locations

  • United Kingdom

  • France

  • Austria

  • Spain

  • Brazil

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • C1 Inhibitor Deficiency

  • Hereditary angioedema

Biomarkers

  • N/A

Drug/Treatment

  • Icatibant

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01034969

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved